

September 25, 2023  
Fuji Pharma Co., Ltd.

### Marketing Approval for Ustekinumab Biosimilar

Tokyo, Japan - Fuji Pharma Co., Ltd. ("Fuji") has announced that it has received marketing approval for a new biosimilar to Stelara® (ustekinumab). The newly approved drug, USTEKINUMAB BS 45mg Syringe for S.C. Injection 「F」 ("Product"), has been indicated for the treatment of psoriatic disease where existing treatments are not sufficiently effective as well as for treatment of psoriatic arthritis.

This Product is the first to emerge from Fuji's collaboration with Alvotech (head office: Iceland), facilitated by a capital and business alliance agreement between Fuji and Alvotech. Including this Product, Fuji and Alvotech have a total of seven biosimilar products under development for the Japanese market.

Aligned with our Mid-Term Business Plan (FY9/2020-9/2024), Fuji's objective is to become the top biosimilar manufacturer in Japan by FY9/2029. To that end, Fuji plans to broaden its biosimilar product range to serve the Japanese healthcare market, benefiting patients, medical professionals, and healthcare economics..


Therapeutic category	Product name	Original drug
Human anti-human IL-12/23p40 monoclonal antibody preparation	USTEKINUMAB BS 45mg Syringe for S.C. Injection 「F」	Stelara® Subcutaneous Injection 45mg Syringe

#### [About Alvotech]

Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech's current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth

therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit [www.alvotech.com](http://www.alvotech.com). None of the information on the Alvotech website shall be deemed part of this press release.

**[Status of biosimilars agreed with Alvotech ]**



**Note**

The financial forecasts and other projections provided in this release are based on information available at the time of its compilation and it therefore contains an element of uncertainty and potential risks. Actual results may differ significantly from these forecasts for a number of reasons. It should also be noted that the views and/or facts presented here may be altered or deleted without prior notification. Information in this release about pharmaceuticals (including items in the pipeline) is not provided for the purpose of marketing or advertising or of supplying medical advice.

**For further information, contact**

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

[fsks@fujipharma.jp](mailto:fsks@fujipharma.jp)